Citi is adding an “upside 90-day catalyst watch” on Arcturus Therapeutics (ARCT) ahead of the Cystic Fibrosis catalyst expected in early Q3. The firm highlights potential upside on a Phase 2 readout from the company’s CF program and keeps an Overweight rating and $47 price target on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics: Buy Rating Affirmed Amid Promising OTC Developments and Upcoming CF Catalyst
- Promising Potential of Arcturus Therapeutics’ mRNA Therapies Drives Buy Rating
- Arcturus Therapeutics Announces Positive Phase 2 Results
- Arcturus announces ‘positive’ interim Phase 2 multiple dose data for ARCT-810
- Positive Outlook on Arcturus Therapeutics Driven by Promising mRNA Advancements and Strategic Developments